NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study

NCT ID: NCT06077812

Last Updated: 2024-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-27

Study Completion Date

2024-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to determine the feasibility of a migraine self-management program.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with migraine seen by neurologists/headache specialists within or affiliated with the NYU Langone Health system will be identified via electronic medical record system, or in person. The investigators will randomize 50 participants to an in-person migraine self-management protocol, or a remote migraine self-management protocol. The investigators will examine benefits through follow-up at 2, 4, and 6 month time points.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Migraine Self-Management Headache Behavioral Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

In-Person Migraine Self-Management

Group Type ACTIVE_COMPARATOR

RELAXaHEAD Smartphone App

Intervention Type BEHAVIORAL

Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

In-Person Training

Intervention Type BEHAVIORAL

Participants will receive in-person training in migraine self-management techniques.

Remote Migraine Self-Management

Group Type ACTIVE_COMPARATOR

RELAXaHEAD Smartphone App

Intervention Type BEHAVIORAL

Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

Virtual Training

Intervention Type BEHAVIORAL

Participants will receive virtual training in migraine self-management techniques.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RELAXaHEAD Smartphone App

Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

Intervention Type BEHAVIORAL

In-Person Training

Participants will receive in-person training in migraine self-management techniques.

Intervention Type BEHAVIORAL

Virtual Training

Participants will receive virtual training in migraine self-management techniques.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* English speaking. (At this time, the validated app is only available in English.)
* 18-65 years of age
* Meets International Classification of Headache Disorder (ICHD)-3 migraine criteria based on a headache specialist or neurologist
* Headaches for ≥1 year
* Has not begun a new migraine preventative medication in the last month
* Agreement to not make any preventive medication changes from the time of trial start until 3 months after beginning the study (Note - Acute medications may be changed if needed. Changes in preventive and acute medication and the time initiated will be recorded to evaluate the potential for medication confounds)
* 4-29 headache days a month (so the study includes those in whom the investigators typically offer preventive treatment \[\>4 headache days/month\] and those with more frequent migraines including chronic migraine \[15 days or more/month\] but exclude those with continuous headaches)

Exclusion Criteria

* Diagnosis of Medication Overuse Headache (MOH)
* Patients who have had Cognitive Behavioral Therapy, Biofeedback, or other Relaxation Therapy for migraine in the past year
* Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record
* Current opioid or barbiturate use
* PHQ-8 scores greater than 15, indicating a conservative score of moderately severe depressive symptoms based on the PHQ-9 (in this group, more intense psychological intervention targeted to the depression may be needed, as depression is a significant predictor of migraine chronification and people with migraine and comorbid depression are more likely to be refractory to migraine treatments and to develop medication overuse headache)
* Unable or unwilling to follow a treatment program that relies on written and audio-taped materials
* Coronary heart disease, heart attack, stroke, diabetes mellitus Type 1 or II
* Pregnant (because hormonal fluctuations in pregnancy can affect migraine outcomes)
* Other physical limitations which would prevent participating in the standard protocol of biofeedback being studied
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mia T Minen, MD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NYU Langone Health

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22-01149

Identifier Type: -

Identifier Source: org_study_id